Supersymmetric Benchmarks with Non-Universal Scalar Masses or Gravitino Dark Matter

We propose and examine a new set of benchmark supersymmetric scenarios, some of which have non-universal Higgs scalar masses (NUHM) and others have gravitino dark matter (GDM). The scalar masses in these models are either considerably larger or smaller than the narrow range allowed for the same gaugino mass m_{1/2} in the constrained MSSM (CMSSM) with universal scalar masses m_0 and neutralino dark matter. The NUHM and GDM models with larger m_0 may have large branching ratios for Higgs and/or $Z$ production in the cascade decays of heavier sparticles, whose detection we discuss. The phenomenology of the GDM models depends on the nature of the next-to-lightest supersymmetric particle (NLSP), which has a lifetime exceeding 10^4 seconds in the proposed benchmark scenarios. In one GDM scenario the NLSP is the lightest neutralino \chi, and the supersymmetric collider signatures are similar to those in previous CMSSM benchmarks, but with a distinctive spectrum. In the other GDM scenarios based on minimal supergravity (mSUGRA), the NLSP is the lighter stau slepton {\tilde \tau}_1, with a lifetime between ~ 10^4 and 3 X 10^6 seconds. Every supersymmetric cascade would end in a {\tilde \tau}_1, which would have a distinctive time-of-flight signature. Slow-moving {\tilde \tau}_1's might be trapped in a collider detector or outside it, and the preferred detection strategy would depend on the {\tilde \tau}_1 lifetime. We discuss the extent to which these mSUGRA GDM scenarios could be distinguished from gauge-mediated models.Comment: 52 pages LaTeX, 13 figure

Factors Associated with Revision Surgery after Internal Fixation of Hip Fractures

Background: Femoral neck fractures are associated with high rates of revision surgery after management with internal fixation. Using data from the Fixation using Alternative Implants for the Treatment of Hip fractures (FAITH) trial evaluating methods of internal fixation in patients with femoral neck fractures, we investigated associations between baseline and surgical factors and the need for revision surgery to promote healing, relieve pain, treat infection or improve function over 24 months postsurgery. Additionally, we investigated factors associated with (1) hardware removal and (2) implant exchange from cancellous screws (CS) or sliding hip screw (SHS) to total hip arthroplasty, hemiarthroplasty, or another internal fixation device. Methods: We identified 15 potential factors a priori that may be associated with revision surgery, 7 with hardware removal, and 14 with implant exchange. We used multivariable Cox proportional hazards analyses in our investigation. Results: Factors associated with increased risk of revision surgery included: female sex, [hazard ratio (HR) 1.79, 95% confidence interval (CI) 1.25-2.50; P = 0.001], higher body mass index (fo

Timetable edge finding filtering algorithm for discrete cumulative resources

Abstract. This paper presents new Edge Finding algorithm for discrete cumulative resources, i.e. resources which can process several activities simultaneously up to some maximal capacity C. The algorithm has better time complexity than the current version of this algorithm: O(kn log n) versusO(kn 2)wheren is number of activities on the resource and k is number of distinct capacity demands. Moreover the new algorithm is slightly stronger and it is able to handle optional activities. The algorithm is based on the Θ-tree – a binary tree data structure which already proved to be very useful in filtering algorithms for unary resource constraints.

The phylogenetic relationships among infraorders and superfamilies of Diptera based on morphological evidence

10.1111/j.1365-3113.2012.00652.xSystematic Entomology381164-179SYEN

DEVELOPMENT OF POTENTIAL ALTERNATIVES TO THE DRAIZE EYE TEST - THE CTFA EVALUATION OF ALTERNATIVES PROGRAM - PHASE-II - REVIEW OF MATERIALS AND METHODS

The CTFA Evaluation of Alternatives Program is a multi-year effort, organised by the CTFA Animal Welfare Task Force, designed to evaluate the performance of currently promising in vitro (alternative) methods to the Draize eye irritancy test. The sole criterion for inclusion of a particular test is that it shows some initial promise as an alternative to the Draize eye test, and that it is under evaluation or development by a participating CTFA member company. Tests are evaluated for their ability to rank and discriminate the ocular irritation potential of prototype cosmetic and personal care formulations compared to the Draize eye test Test materials and in vitro methods currently under evaluation in Phase II of the CTFA Program are described. Additional tests may be included in subsequent phases of the Program, should it be determined that they show particular promise as replacements for specific types of formulation. Conversely (at the discretion of sponsors), tests may be removed from the Program should initial promise be unfulfilled

Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome

Contains fulltext : 172400.pdf (Publisher’s version ) (Open Access)Atypical hemolytic uremic syndrome (aHUS) is caused by alternative complement pathway dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ damage. Based on 2 prospective studies in mostly adults and retrospective data in children, eculizumab, a terminal complement inhibitor, is approved for aHUS treatment. Here we prospectively evaluated efficacy and safety of weight-based dosing of eculizumab in eligible pediatric patients with aHUS in an open-label phase II study. The primary end point was complete TMA response by 26 weeks. Twenty-two patients (aged 5 months-17 years) were treated; 16 were newly diagnosed, 12 had no prior plasma exchange/infusion during current TMA symptomatology, 11 received baseline dialysis, and 2 had prior renal transplants. By week 26, 14 achieved a complete TMA response, 18 achieved hematologic normalization, and 16 had 25% or better improvement in serum creatinine. Plasma exchange/infusion was discontinued in all, and 9 of the 11 patients who required dialysis at baseline discontinued, whereas none initiated new dialysis. Eculizumab was well tolerated; no deaths or meningococcal infections occurred. Bone marrow failure, wrist fracture, and acute respiratory failure were reported as unrelated severe adverse events. Thus, our findings establish the efficacy and safety of eculizumab for pediatric patients with aHUS and are consistent with proposed immediate eculizumab initiation following diagnosis in children

The CFTA evaluation of alternatives program: An evaluation of in vitro alternatives to the Draize primary eye irritation test. (Phase III) surfactant-based formulations

The CTFA Evaluation of Alternatives Program is an evaluation of the relationship between data from the Draize primary eye irritation test and comparable data from a selection of promising in vitro eye irritation tests. In Phase III, data from the Draize test and 41 in vitro endpoints on 25 representative surfactant-based personal care formulations were compared. As in Phase I and Phase II, regression modelling of the relationship between maximum average Draize score (MAS) and in vitro endpoint was the primary approach adopted for evaluating in vitro assay performance. The degree of confidence in prediction of MAS for a given in vitro endpoint is quantified in terms of the relative widths of prediction intervals constructed about the fitted regression curve. Prediction intervals reflect not only the error attributed to the model but also the material-specific components of variation in both the Draize and the in vitro assays. Among the in vitro assays selected for regression modelling in Phase III, the relationship between MAS and in vitro score was relatively well defined. The prediction bounds on MAS were most narrow for materials at the lower or upper end of the effective irritation range (MAS = 0-45), where variability in MAS was smallest. Thus, the confidence with which the MAS of surfactant-based formulations is predicted is greatest when MAS approaches zero or when MAS approaches 45 (no comment is made on prediction of MAS > 45 since extrapolation beyond the range of observed data is not possible). No single in vitro endpoint was found to exhibit relative superiority with regard to prediction of MAS. Variability associated with Draize test outcome (e.g. in MAS values) must be considered in any future comparisons of in vivo and in vitro test results if the purpose is to predict in vivo response using in vitro data